Use our Tumor Relapse Assay to classify the kinetics of cancer relapse potential in vitro
Leverage InSphero's tumor relapse assay to simultaneously determine the response of a tumor to your drug as well as the kinetics of tumor re-growth (relapse) following removal of the drug in vitro.
We use phenotypic (size-based) assessment of spheroid growth by bright-field imaging to allow continuous, non-lytic monitoring of spheroid growth over time through our advanced tumor relapse assay.
Tumor Relapse Assay Characterization Data
InSphero tumor relapse assay: assess cancer recurrent potential following removal of the drug in vitro.
Example tumor relapse kinetics for Doxorubicin showing recovery of HCT-116 tumor spheroid growth following single treatment (pulsed-green line) at the EC50 dose, compared to repeat-dosing over 10 days at the max response dose (gray line) or vehicle control (black line). Growth constants are used to determine relapse classification values at EC20 and EC50 values.
Learn more about our tumor relapse assay.
Tumor Relapse Assay at a Glance
Download our brochure for details on the standard protocol.
Service Report includes
- ATP-based dose-response curves
- Growth kinetics over time (bright-field imaging)
- Potency (EC20 and EC50) values, efficacy (max response), growth constants, and relapse classification values at EC20 and EC50 dosings
| Catalog # | Description |
|---|---|
| SP-01-043-01 | 3D InSight™ Tumor Relapse Assay Service (1 compound, 3 controls, 1 model) |
